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Abstract A number of studies have already demonstrated the clinical effectiveness offormoterol when used as main- 
tenance therapy in patients requiring both a j82-agonist with a long duration of action and a regular inhaled corticosteroid. 
Howeven formoterol has a unique mechanism of action that gives it both fast- and long-acting properties. Hence the 
question arises as to whether formoterol can also be used as first-line reliever medication in addition to maintenance 
thera W. Compared with terbutaline, formoterol used as needed in steroid-treated mild to moderate asthma has super- 
ior efficacy, not only significantly improving peak flow, but also the exacerbation rate. In moderate to severe asthma, 
formoterol used as needed has demonstrated efficacy comparable with salbutamol and terbutaline in improving symp- 
toms and lung function. Single doses offormoterol have also been shown to result in protection against exercise-induced 
bronchoconstriction for periods upto 12 h. Furthermore, bronchoprotection was maintained following repeated dosing, 
although further research is needed to confirm the duration of protection achieved with frequent and regular use. Initial 
research also suggests that formoterol is as effective and well tolerated as terbutaline in the treatment of acute asthma 
attacks. The evidence presented supports the use of formoterol on an as-needed basis for effective asthma control. 
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INTRODUCTION 
Formoterol is a selective/~2-adrenoceptor agonist with a 
unique mechanism of action--it is the only/~2-agonist 
with both fast- and long-acting properties. This can be 
explained by the pharmacology of formoterol, which dif- 
fers from both the long-acting /~2-agonist, salmeterol, 
and the short-acting/82-agonists (e.g. salbutamol)(I). For- 
moterol is moderately lipophilic, enabling enough drug, 
when inhaled, to diffuse into the lipid bilayer and to pro- 
duce a long duration of action. On the other hand, for- 
moterol is sufficiently hydrophilic to bind rapidly to the 
cell surface/82-receptor, resulting in a fast onset of ac- 
tion. In contrast, salmeterol is highly lipophilic and salbu- 
tamol is hydrophilic. 
All asthmatic patients may suffer from episodes re- 
quiring as-needed medication for rapid bronchodilation. 
The three main situations in which this would be neces- 
sary in normally well-controlled patients on mainte- 
nance therapy is to relieve symptoms caused by specific 
stimuli, to prevent exercise-induced bronchoconstric- 
tion (EIB) or to reverse an acute asthma exacerbation. 
Present asthma guidelines currently position short-act- 
ing/~2-agonists as preferred reliever medication. 
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For a newer agent to become established as a drug of 
choice for a particular indication, additional efficacy or 
safety benefits over currently available treatments need 
to be demonstrated. The unique pharmacological profile 
of formoterol may allow it to be used as an effective treat- 
ment in both as-needed and maintenance therapy. Several 
studies have shown formoterol to have a bronchodilating 
effect with onset and degree of bronchodilation similar to 
that produced by salbutamol (2,3). Moreover, the duration 
of the bronchodilation is at least 12 h, much longer than 
with salbutamol but similar to salmeterol (3). 
This paper will review the evidence for the effective- 
ness of formoterol used as needed for fast symptom re- 
lief, EIB and acute asthma attacks. 
CL IN ICAL  EFF ICACY OF  AS-NEEDED 
FORMOTEROL IN SYMPTOM 
CONTROL 
Several studies now support the use of formoterol as re- 
lief medication, with or without maintenance therapy, in 
different patient groups. 
Mild to moderate persistent asthma 
A recent study was conducted to compare the safety 
and efficacy of formoterol Turbuhaler '~ 4.5 tlg vs. terbu- 
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talineTurbuhale¢ ~ 0.5 mg when used as needed, up to 12 
inhalations daily (4). The patients included in the study 
had poorly controlled asthma, and despite taking inhaled 
steroids (mean daily dose 870~g) they required on aver- 
age 3-8  inhalations of a short-acting/~2-agonist per day. 
The primary endpoint was time to first severe exacerba- 
t ion~ef ined  as requiring treatment with oral corticos- 
teroids or a decrease in morning or evening peak 
expiratory flow (PEF) of more than 30% below baseline 
on two consecutive days. 
The results of this double-blind, randomized study re- 
vealed that significantly fewer patients in the formoterol 
group suffered a severe exacerbation within the 12-week 
follow-up period (P=0.013) (Fig. I). Also, the number of in- 
halations of as-needed medication decreased in both 
groups, but to a greater degree in the formoterol group 
(P=0.0003). Both treatments were well tolerated, with 
no significant differences between the two groups. In a 
further analysis of the study data, the formoterol group 
showed a greater improvement in the Asthma Quality of 
Life Questionnaire (AQLQ) score compared with terbu- 
taline (P=0.004) (5). 
Moderate to severe persistent asthma 
Patients requiring a combination of regular inhaled ster- 
oids and long-acting/~2-agonists may also need additional 
inhalations of a fast-acting /~2-agonist, to be taken as 
needed for symptom relief. Patients could therefore take 
formoterol for both maintenance and as-needed therapy, 
reducing the number of inhalers necessary whilst main- 
taining efficacy. This could increase convenience and re- 
duce confusion for both patients and their general 
practitioners, contributing to better adherence to ther- 
apy. 
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Figure I. Kaplan Meier plot showingthe estimated probabil- 
ity of remaining without a severe asthma exacerbation in pa- 
tients treated with formoterol and terbutaline as needed (4) 
The as-needed use of formoterol and salbutamol was 
compared in a crossover study of 16 patients with moder- 
ate to severe asthma, 15 of whom needed high doses of 
inhaled steroids (600-1600/~g) (6). For each 4-week per- 
iod, the patients received either formoterol 24#g 
(pMDI) or salbutamo1400 #g, both twice daily, plus addi- 
tional inhalations of the same drug as needed. It was 
found that even though patients in the formoterol group 
needed signifcantly fewer relief inhalations than patients 
receiving salbutamol (P<0.01), they still experienced 
fewer nights with disturbed sleep, and had improved 
symptom scores and lung function (measured by morn- 
ing and evening PEF) (P < 0.01). 
To ensure that tolerance did not develop, a reversibil- 
ity test was carried out at the end of each 4-week treat- 
ment period. There was no statistically significant 
difference between the mean maximum forced expira- 
tory volume in I second (FEVI) values obtained in each 
study period, indicating that there was no loss in bronch- 
odilatory effect after using either drug. 
In a 12-week study, formoterol 4.5/~g as needed was 
compared with terbutaline 0.5 mg as needed in patients 
with moderate asthma already receiving inhaled corti- 
costeroids and formoterol (9fig twice daily) as mainte- 
nance therapy (7). The number of additional reliever 
inhalations needed was similar in both groups. In addition, 
there were no differences between groups with regard to 
PEF, FEVI and time to first severe asthma exacerbation. It 
was concluded that formoterol as needed was as safe and 
well tolerated as terbutaline as needed when taken with 
formoterol maintenance therapy. 
Thus, when formoterol is used regularly and as first- 
line reliever medication it has the added advantage, com- 
pared with other fast-acting agents, that the number of 
inhalers required is reduced with no loss of efficacy (8). 
In addition, patients have expressed a preference for this, 
more convenient, treatment regimen. 
PREVENTION OF 
EXERCISE-INDUCED 
BRONCHOCONSTRICTION 
The efficacy of a medication in EIB is an important con- 
sideration in deciding which as-needed therapy to 
choose.The duration of protection achieved with formo- 
terol was investigated in a crossover study of 27 children 
with EIB, 17 of whom were receiving inhaled corticoster- 
oids (120-750fig) (9). Formoterol (single doses, 4.5#g 
and 9 Fig) was compared with both terbutaline (0.5 mg) 
and placebo using the bronchial response to exercise (In- 
deXEIB). Each dose of formoterol offered up to 12 h pro- 
tection against the fall in FEV~ observed in the placebo 
group following exercise challenge (P<0.001 at 12h 
for both doses) (Fig. 2).The protection offered by formo- 
terol after 4 h was equivalent o that offered 15 min post- 
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Effect of formoterol and terbutaline on exercise- 
induced bronchospasm (9), 
dose and although the amount of protection achieved 8 
and 12 h after dosing was diminished, there was still a sta- 
tistically significant degree of protection compared with 
placebo (P=0.003 for formoterol 4.5pg at 8h and 
P <0.001 at all other doses and time points). In contrast, 
terbutaline exhibited a maximal degree of bronchopro- 
tection at 15 min similar to formoterol (3.34% vs. 5.40% 
and 2.50% for formoterol 4.5 pg and 9 #g, respectively), 
but the effect decreased 4 h post-dose; after this time 
point, formoterol was significantly superior (formoterol 
4.5#g: P=0.009, P=0.01 and P<0.001 at 4, 8 and 12h, re- 
spectively; formoterol 9 #g: P < 0.001 at 4, 8 and 12 h). 
A concern with prolonged use of any fl2-agonist, parti- 
cularly in EIB, is the development of tolerance due to 
downregulation of the receptors, and it has been argued 
that more profound downregulation would be observed 
following treatment with a long-acting fi2-agonist com- 
pared with a short-acting agonist. Lipworth et a/. (10) 
have studied the phenomenon of methacholine-induced 
bronchoconstriction in a 2-week study of patients trea- 
ted with three doses of formoterol (9#g once daily, 
4.5#g twice daily and 18#g twice daily), terbutaline 
(0.5 mg four-times daily) or placebo. After the first dose, 
all active drug groups achieved protection against 
methacholine-induced bronchoconstriction, with all 
three doses of formoterol providing a greater degree of 
protection than terbutaline. Over the study period tol- 
erance did develop; in all the formoterol groups a larger 
reduction in bronchoprotection was observed than in 
the terbutaline group, with the greatest reduction seen 
in the formotero118 #g twice-daily group. However, after 
2 weeks of continuous dosing significant bronchoprotec- 
tion compared with placebo was still observed in all ac- 
tive drug groups, with no differences between the 
formoterol and terbutaline groups. 
These results were observed following dosing with a 
direct stimulus, i.e. methacholine, whereas exercise is 
an indirect stimulus acting like adenosine monopho- 
sphate (AMP), producing its bronchoconstrictive ffect, 
at least in part, via release of mediators from inflamma- 
tory cells, in particular mast cells. As inflammatory cells 
have a lower number and a slower turnover of fi2-recep- 
tors than airways smooth muscle, more pronounced de- 
velopment of tolerance to the effects of a fl2-agonist 
might be expected with an indirect stimulus. This has 
been observed in a crossover study in patients treated 
with either terbutaline 500 #g four-times daily or place- 
bo and challenged with inhaled methacholine or AMP 
(11). Terbutaline produced significant bronchoprotection 
to both methacholine and AMP challenge compared with 
placebo, but a more rapid decline in protection against 
AMP was observed over the 7-day treatment period 
compared with methacholine. Importantly, however, 
the initial degree of protection against AMP achieved 
was greater than the protection achieved against metha- 
choline challenge (P < 0.001). 
This added degree of bronchoprotection towards 
AMP is probably due to mast-cell stabilization on top of 
functional antagonism at the smooth muscle level, result- 
ing in substantially better protection against indirect 
rather than direct stimuli. This additional effect, which 
arguably requires a full fi2-agonist, has also been seen 
with formoterol but not with salmeterol (12). 
One study has evaluated the duration of the broncho- 
protective effects of formoterol (9yg), terbutaline 
(0.5 mg) and placebo in EIB in patients receiving regular 
treatment with formoterol and inhaled corticosteroids 
(13).The results show that formoterol maintains superior 
bronchoprotective activity compared with terbutaline 
for up to 12 h after inhalation. However, in this study no 
baseline data prior to starting formoterol as mainte- 
nance treatment were available. Hence, the possible de- 
velopment of any relevant degree of tolerance could not 
be evaluated. 
This aspect needs to be further examined. Impor- 
tantly, however, it has to be noted, that irrespective of 
whether repeated use of formoterol results in a reduc- 
tion of the duration of protection against EIB achieved, 
the effects are still more prolonged than after inhalation 
of a short-acting/G2-agonist uch as terbutaline. 
TREAT HENT OF ACUTE ATTACKS 
Another important use for as-needed medication is the 
treatment of acute asthma attacks. FormoterolTurbuha- 
ler ~' 9#g has been shown to have a similar profile to sal- 
butamol Turbuhaler @ 50 #g in reversal of methacholine- 
induced severe bronchoconstriction (14). Both drugs 
were shown to have a significantly faster onset than sal- 
meterol (P=0.01) (Fig. 3).The authors concluded that for- 
moterol, but not salmeterol, could be used as an 
alternative to salbutamot in acute asthma attacks. 
S20 RESPIRATORY MEDICINE 
Methacholine-induced 
bronchoconstiiction 
110 
100 
" 90 
80 
70 
>- 60 
50 
40 
Salmeterol 50 ~tg 
. ~ --c- Placebo 
Inhalation 
I I I I I I I I I I I I I I 
-5 5 15 25 35 45 55 
Time (min) 
65 
Figure 3. Reversal of methacholine-induced bronchocon- 
striction following administration of formoterol Turbuhaler ~ 
9 ltg, salbutamol Turbuhaler '"' 50#g, salmeterol Diskhaler ~R~ 
50 #g or placebo (14). 
The ability of formoterol and terbutaline to restore 
peak flow was studied in patients admitted to an emer- 
gency department following an acute attack (15). The pa- 
tients received oxygen and were randomized to receive 
either formoterol (20 inhalations of 4.5 pg, total dose 
90 I~g) or terbutaline (20 inhalations of 0.5 mg, total dose 
10 mg) on six occasions during a 180-minute period. 
After 90 minutes all patients received 40 mg of methyl- 
prednisolone intravenously.There was no statistically sig- 
nificant difference between the groups in improvement 
of lung function measured by mean FEV, but the de- 
crease in plasma potassium levels seen in patients was 
less pronounced in the formoterol group. Moreover, pa- 
tients attending an emergency-care setting with dys- 
pnoea tend to be anxious and have a higher heart 
rate--this effect was accentuated in the terbutaline 
group compared with patients in the formoterol group. 
This study suggests that formoterol is as effective as ter- 
butaline in treating an acute asthma attack and is also 
well tolerated. Further research is needed to confirm 
and extend this finding. 
CONCLUSIONS 
Available data confirm that formoterol is an effective 
treatment when used as-needed in asthma control. In pa- 
tients with persistent asthma, it has been shown to be as 
effective as traditional short-acting ~2-agonists and may 
reduce the number of inhalers needed whilst maintaining 
efficacy. In turn, this may prevent confusion for both the 
physician and the patient, as well as improving conveni- 
ence and adherence to therapy. In addition, formoterol 
used as needed reduced the rate of asthma exacerba- 
tions in moderate asthma, which may result in it being 
more cost-effective than other traditional as-needed 
t reatments .  
In the  prevent ion  of  EIB, fo rmotero l  p rov ided a high 
degree of  p ro tect ion ,  w i th  a longer  durat ion  than that  
achieved w i th  terbuta l ine .  Formotero l  has also demon-  
s t ra ted  effect iveness in the  t reatment  of  pat ients suffer- 
ing f rom an acute asthma at tack  who requ i re  emergency  
t reatment ,  but  more  studies in this area are needed to  
suppor t  this f inding. In summary,  the  evidence presented 
suppor ts  the  use of  fo rmotero l  on an as-needed basis for  
ef fect ive asthma contro l .  
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